

## **Supervisory Board changes announced**

**Arnhem, the Netherlands, February 13, 2006 — Akzo Nobel is to propose a number of changes to its Supervisory Board at the Annual General Meeting of Shareholders being held in April.**

As previously announced, Aarnout Loudon will resign from the Supervisory Board as of May 1, having been its Chairman since 1995. His departure brings to an end a long and distinguished career with Akzo Nobel and the company wishes to express its gratitude and appreciation for his invaluable contribution.

He will be succeeded as Supervisory Board Chairman by Maarten van den Bergh, who is currently Deputy Chairman, as well as being Chairman of Lloyds TSB Group plc and a non-executive Director of Royal Dutch Shell plc, BT Group and British Airways. Karel Vuursteen will take over the position of Deputy Chairman. A former CEO of Heineken, Vuursteen is also a member of the Supervisory Boards of, among others, ING Group and AB Electrolux.

It will be proposed at the AGM on April 25 that Antony Burgmans—Chairman of Unilever N.V. and Unilever plc—and Louis R. Hughes—the Chief Executive Officer of GBS Laboratories—be appointed to Akzo Nobel's Supervisory Board for a four-year term, as from May 1.

"We are looking forward to Antony Burgmans and Louis R. Hughes becoming valued members of Akzo Nobel's Supervisory Board," said Chairman-elect, Maarten van den Bergh. "Both have a wealth of professional experience and will bring strong business acumen to our organization."

Born in the Netherlands, Burgmans is also a member of the Supervisory Board of ABN AMRO Bank, member of the International Advisory Board of Allianz AG and a non-executive director of BP plc.

A graduate of Harvard University, Hughes is a former Executive Vice-President of General Motors Corp. (USA) and ex-President and CEO of Lockheed Martin. He also worked for the U.S. Department of State in Afghanistan and was CEO of Adam Opel AG.

In accordance with the rotation schedule, Karel Vuursteen and Alain Mérieux will step down from the Supervisory Board at April's Annual General Meeting of Shareholders. Both will be proposed for reappointment for another term.

- - -

**Note for the editor**

Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also listed on the Dow Jones Sustainability Indexes. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,500 people and conduct our activities in four segments – human and animal health, coatings and chemicals – subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the first quarter will be published on April 20, 2006.

Internet: [www.akzonobel.com](http://www.akzonobel.com)

**Not for publication – for more information**

Please contact the Corporate Media Relations department if you require a resume and/or a photograph of Messrs. Burgmans and Hughes.

Akzo Nobel nv  
Corporate Media Relations, tel. +31 26 366 43 43  
Contact: Patricia Janssen

**Safe Harbor Statement\***

This report contains statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website [www.akzonobel.com](http://www.akzonobel.com). The 2005 Annual Report on Form 20-F will be available in the second quarter of 2006.

\* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.